Agency of the United States Department of Health and Human Services
POPULARITY
Categories
357 episodes with fda
281 episodes with fda
183 episodes with fda
247 episodes with fda
229 episodes with fda
126 episodes with fda
183 episodes with fda
112 episodes with fda
147 episodes with fda
150 episodes with fda
273 episodes with fda
183 episodes with fda
178 episodes with fda
185 episodes with fda
53 episodes with fda
82 episodes with fda
75 episodes with fda
90 episodes with fda
65 episodes with fda
62 episodes with fda
135 episodes with fda
55 episodes with fda
70 episodes with fda
107 episodes with fda
107 episodes with fda
61 episodes with fda
68 episodes with fda
36 episodes with fda
96 episodes with fda
44 episodes with fda
50 episodes with fda
65 episodes with fda
44 episodes with fda
42 episodes with fda
105 episodes with fda
43 episodes with fda
64 episodes with fda
50 episodes with fda
47 episodes with fda
51 episodes with fda
61 episodes with fda
97 episodes with fda
78 episodes with fda
41 episodes with fda
38 episodes with fda
59 episodes with fda
64 episodes with fda
56 episodes with fda
55 episodes with fda
97 episodes with fda
73 episodes with fda
59 episodes with fda
49 episodes with fda
99 episodes with fda
In this user's guide to sleep trackers, learn the science behind how they work using motion and optical sensors as Matt explains the key metrics of Sensitivity, Specificity, and Accuracy. Revealing why most trackers overestimate sleep by failing to detect wakefulness, he reveals the crucial difference between a device's flawed "absolute accuracy" and its more valuable "relative accuracy," which highlights the importance of tracking long-term trends over single-night scores.Matt goes on to examine peer-reviewed data on the Oura Ring, Apple Watch, and Whoop, and introduces the highly accurate, FDA-cleared Happy Ring with its personalized algorithm. Beyond the specs, learn why consistency and form factor are more important than chasing perfect accuracy. The episode also covers the pitfalls of tracking, from the anxiety of "Orthosomnia" to demographic biases in sensor tech, providing a complete guide to choosing and using your device effectively.Please note that Matt is not a medical doctor, and none of the content in this podcast should be considered medical advice in any way, shape, or form, nor prescriptive in any way.Podcast partner, AG1, is one that Matt relies upon for his foundational nutrition. Their new science-backed Next Gen formula features upgraded probiotics, vitamins, and minerals. Start your subscription today to get a FREE bottle of Vitamin D3+K2 and 5 free travel packs with your first order at drinkag1.com/mattwalker.Another sponsor, Shopify, made launching Matt's merchandise incredibly smooth with its integrated sales system. Shopify simplifies everything from online stores to in-person sales. Start your exclusive trial and see for yourself at shopify.com/mattwalker.In a supplement industry where trust is critical, Matt uses podcast partner Puori. Their protein powders are free from hormones, GMOs, and pesticides, with every single batch third-party tested for over 200 contaminants. For protein you can trust, save 20% at puori.com/mattwalker.As always, if you have thoughts or feedback you'd like to share, please reach out to Matt:Matt: Instagram @drmattwalker, X @sleepdiplomat, YouTube: https://www.youtube.com/channel/UCA3FB1fOtY4Vd8yqLaUvolg
The advent of artificial light is obliterating women's moon-driven menstrual cycle rhythms; When the triple whammy of cataracts, glaucoma, and macular degeneration strikes; Why can systolic blood pressure spike erratically? Are wrist and finger wearables for blood pressure ready for prime time? Nearly half of drivers killed in crashes have THC in their blood; Drinking bottled water causes surge in plastic micro-particle intake; The common supplement that can supercharge cancer immunotherapy.
With 30 years of medical experience, as well as a passion for health and wellness, Laura Hagen knows the ins and outs of a human body. Her own breast cancer diagnosis in 2023 led her down a path she never anticipatedAs we bring awareness to breast cancer in the month of October, Laura shares her journey from diagnosis, through treatment and post-treatment life. Her perspective and attitude are a powerful remind of the importance of gratitude when faced with a challenge. It's an uplifting conversation sure to inspire you to examine your own approach to difficult situations in life.Connect with Laura:https://facebook.com/llynnhagenWomen's Health and Cancer Act References:Studies reference the dangers of bioidentical hormonescBHT and breast cancer, American Cancer SocietyEndocrine Society's stance on non-FDA-approved estrogenConnect with Michelle:betterbeings.netIG: @betterbeingsusYouTube: Michelle Zellner - Be A Better Being Podcast playlistGet the supplements Michelle can't stop talking about: meet.makewellness.com/?referral=E490A5C07D
This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright take on one of the biggest misinformation waves in popular health media: the rise of “microdosed” GLP‑1s and so‑called “GLP‑1 diets.” As GLP‑1 medications dominate headlines and social media feeds, the hosts cut through the noise to explain what's actually safe, what's marketing hype, and why restrictive diets go against metabolic science. Dr. Cooper reveals how calorie‑cutting research became misinterpreted, how compounded microdoses are being promoted like supplements, and why “just eat less” remains one of the most harmful messages for people trying to improve their metabolic health. From the hormonal backlash of dieting to potentially-dangerous online telehealth shortcuts, this episode exposes how the new era of “skinny shots” and influencer‑driven microdosing campaigns echo decades of failed diet culture.Key Takeaways:GLP‑1 medications were never meant to be microdosed — these are serious prescription treatments, not vitamin‑like supplements.“GLP‑1 diets” persist because clinical trials paired the drugs with low‑calorie plans — but science hasn't yet proven those restrictions help long‑term.Chronic calorie restriction weakens metabolism, disrupts hormones, and sets up “defensive weight gain.”Compounded or telehealth‑prescribed GLP‑1 versions are often untested and can be risky; many forms haven't even been through FDA approval.Real progress comes from fueling your metabolism — eating enough, exercising with support, and stabilizing your brain's hunger signals.Personal Stories & Practical Advice:Andrea opens up about the challenge of “mechanical eating” on GLP‑1 therapy — remembering to eat even when not hungry — while Mark shares how his own food relationship transformed once he focused on fueling, not restriction. Dr. Cooper emphasizes her 25‑year‑old shift away from calorie‑cutting, showing how patients thrive when metabolism is strengthened, not starved.Resources from the episode:Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go (and stay) away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.Check out our new website where you can ask a mailbag question.Have a question for Dr. Cooper, a show idea, feedback, or just want to connect? Email us at questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com.Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.
In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML). Join us as we dive into the essential aspects of CML treatment, including: • The importance of initial workup and bone marrow biopsy in diagnosing CML. • Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib. • Patient-centered decision-making and how to align treatment options with individual patient goals. • Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD). • The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities. • Insights into the role of transplant in accelerated and blast phases of CML. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights. #CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes
Matt Dowling is the Chief Scientific Officer and Director at Medcura Team. Matt completed his graduate work at the Fischell Department of Bioengineering at the University of Maryland (UMD), after completing his undergrad in Chemical Engineering from the University of Notre Dame. At UMD, he was awarded the Fischell Fellowship in Biomedical Engineering for his innovative ideas in drug delivery systems. Matt then co-created gel-e, a novel biomaterial platform, raising several initial grants to develop the technology and to launch Medcura as a corporate entity. Matt was the recipient of the Dean's Doctoral Research Award from the UMD Clark School of Engineering for his work on chitosan-based self-assembled soft materials for use in wound treatment. He has been the Principal Investigator on $10 million in non-dilutive grant awards to Medcura; these have been used to achieve 5 FDA clearances, 2 Breakthrough Device Designations, 28 issued patents, and 10+ peer-reviewed publications in high-impact journals. Matt's work has been featured on several US and international media outlets including the BBC TV program, Brave New World with Stephen Hawking. He's also the lead vocalist in the band, Swoll.Swollhttps://www.swollmusic.com/Light the NightLLS is on a mission to cure blood cancers and improve quality of life for the nearly 1.7 million people in the U.S. living with or in remission from blood cancer.Help Team Zavadowski reach our fundraising goal! Thank you for your generous donations:https://pages.lls.org/ltn/fdk/Montcomd25/rsmith--Get in touch: robinsmithshow@gmail.comCall the hotline: +1 (301) 458-0883Follow Robin on Insight Timer: https://insighttimer.com/robinsmithBecome a supporter on Patreon: https://www.patreon.com/therobinsmithshowGot a question? We'd love to hear from you!
Send us a textWe welcome back Veru's CEO Mitch Steiner to our latest WTR Small-Cap Spotligh podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.
In this episode of Growing Older Living Younger, Dr. Gillian Lockitch speaks with Dr. Bruce Gillis about chronic immune system disorders such as fibromyalgia, chronic fatigue syndrome, interstitial cystitis, and long COVID. Dr. Gillis shares how his research overturned decades of stigma by proving these conditions are objectively measurable through immune system testing and DNA genomic signatures. The conversation explores the role of epigenetics in disease development, the link between coronaviruses and long COVID, and the discovery of a microbiome-modulating compound that reduces symptoms. Listeners will gain validation, clarity, and practical insights into how accurate diagnosis and targeted therapies can improve quality of life. Dr. Bruce Gillis is a physician-scientist and public health expert whose career spans clinical medicine, research, and academic leadership. After earning his MD from the University of Illinois College of Medicine and his MPH from the Harvard School of Public Health, he completed two residencies and two fellowships before joining the faculty at Harvard Medical School, UCLA, and the University of Illinois. His early work focused on environmental health and toxic exposures, including oversight of the Alaskan oil spill cleanup and aerospace medicine projects. Dr. Gillis later turned his focus to chronic immune system disorders such as fibromyalgia, chronic fatigue syndrome, interstitial cystitis, and long COVID. Through groundbreaking research, his team identified specific white blood cell dysfunctions and unique DNA genomic signatures that objectively prove fibromyalgia and related disorders are real, diagnosable conditions. He pioneered the development of the FibroTest, an FDA-reviewed diagnostic blood test now covered by Medicare and many insurers, and continues to study therapeutic compounds that support microbiome health and improve symptom management. Episode Timeline 00:00 – Welcome & Introduction Podcast focus on aging youthfully; Gillian introduces Dr. Gillis and chronic immune disorders. 05:51 – Dr. Gillis' Journey From rural upbringing to Harvard MD/MPH; work in environmental health, aerospace, and proving fibromyalgia is real. 08:44 – What Are Chronic Immune Disorders? Definitions, stigma, and why current drugs only mask symptoms. 12:17 – Epigenetics & Long COVID How environmental triggers and coronaviruses drive epigenetic DNA changes linked to fibromyalgia and chronic fatigue. 16:40 – Blood-Based Diagnostics Immune system testing, identification of protein deficiencies, and discovery of unique DNA genomic signatures. 18:56 – Comparing Conditions How fibromyalgia, chronic fatigue, and interstitial cystitis differ yet share immune dysfunction. 25:34 – Better Diagnostics for Interstitial Cystitis Blood tests prove 11x more accurate than invasive cystoscopy. 27:15 – Therapies & Lifestyle Nutrition, hydration, and discovery of the mycobacterium-derived compound Imbics that supports microbiome health. 34:40 – Future Directions Expanding research into long COVID and other chronic conditions; improving management, not curing DNA changes. Download your gifts: Mind and Memory Boosting Strategies Connect with Dr. Gillian Lockitch Email: askdrgill@gmail.com Subscribe to Growing Older Living Younger on your favorite podcast platform and leave a review to help others discover the show. Share this episode with friends Learn about Dr. Gillis's work here: www.thefibrotest.com www.imbxx.com www. the1test.com
AABP Executive Director Dr. Fred Gingrich is joined by Dr. Chris Ashworth, Global Veterinarian for Zinpro Performance Minerals and Dr. Dave Sjeklocha, technical services veterinarian for Merck Animal Health to discuss New World Screwworm (NWS). Recently, the United States Animal Health Association and National Institute of Animal Agriculture hosted an NWS symposium in Kansas City which was sponsored by the American Veterinary Medical Foundation, Merck Animal Health and Elanco. Both of our guests attended and are providing an update from that symposium. NWS was recently discovered in Nuevo Leon, Mexico which is 70 miles south of the U.S.-Mexico border. The infected animal was a feedlot steer that was detected with larvae upon arrival at the feedlot. Mexican authorities have restrictions on animal movements both at the point of origin and arrival. The life cycle of the NWS fly is about 3 weeks. Fertilized eggs are laid in packets of 200-350 eggs that hatch in 12-21 hours with the emergence of larvae within 3 days. Two important aspects of the life cycle are that female flies mate and lay eggs once, then die and they lay eggs in fresh wounds, not decaying tissue like other fly strikes. The larvae burrow deep into wounds and cause significant destruction which can result in the animal dying of septicemia in 1-2 weeks. It is important to inspect for larvae and remove all of them, placing them in alcohol to kill them. The USDA continues to work with Mexican authorities to protect the U.S. from this fly. Releasing sterile male flies works based on history of control of this pest, but the current production rate of 110 million per week is not enough to control the areas that have the fly. It is also important to remember that half of the sterile flies are females, although scientists are working to try to produce only male flies to increase production. The U.S. is also constructing a facility in Texas, but the timeline for completion to release of flies is 2-3 years. The most important thing veterinarians can do is to inspect animals aggressively. Pay special attention to any wounds – superficial wounds or scrapes, foot rot lesions, open umbilical cords, wounds in the vulva from calving, castration wounds or dehorning sites. Veterinarians and producers should remain hypervigilant and report any suspicious wounds or larvae and contact their state animal health official. Treatment involves the use of avermectin products and doramectin has received emergency use authorization for NWS by FDA. Fly control and wound care is also very important for control of this infestation. AABP members can also view the presentation from Dr. Bud Dinges at the 2025 AABP Annual Conference in Omaha by going to the NWS page on the AABP website (https://aabp.org) as well as other NWS resources.
CAR T-cell therapy is a groundbreaking cancer treatment that reprograms a patient's own immune cells to recognize and destroy cancer. First approved by the FDA in 2017, it's already shown success in patients with blood cancers that no longer respond to standard treatments. While the therapy can cause serious side effects, our expert this week –a pioneer of this therapy– discusses the future of using this powerful new weapon against cancer. Learn more about your ad choices. Visit megaphone.fm/adchoices
Is the mental health crisis fueled by drugs meant to fix it? Despite a 450% surge in antidepressant use, mental health outcomes are worsening especially among young adults. Dr. Josef Witt-Doerring, a psychiatrist and expert on drug-tapering, warns SSRIs may be linked to rising violence. Dr. Witt-Doerring points to FDA corruption and psychiatry's focus on quick-fix prescriptions over root-cause care, like nutrition and trauma support. He critiques lifelong drug reliance and severe withdrawal effects, pushing for reforms including better informed consent and integrating life skills into treatment to address the spiraling crisis. Leland Vittert is host of On Balance with Leland Vittert and NewsNation's chief Washington anchor. When Leland was diagnosed with autism, his father quit his job to coach him full-time in social skills and humor. Later, Leland became a foreign correspondent and anchor at Fox News before getting his own show on NewsNation. He tells his story in the book “Born Lucky: A Dedicated Father, A Grateful Son, and My Journey with Autism“. Learn more at https://bornluckybook.com and https://x.com/lelandvittert Dr. Josef Witt-Doerring is a board-certified psychiatrist and former FDA medical officer. As Medical Director of TaperClinic, he specializes in safe de-prescription of psychiatric medications and recovery from psychiatric drug injury. He previously worked for Janssen Pharmaceuticals (Johnson & Johnson) and the FDA. Follow at https://x.com/drjosefWD NOTE: Suddenly stopping mental health medications may cause dangerous side effects or withdrawals. Only start or stop these medications under the direction of your physician. 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices
What’s Trending: Seattle businesses look to private security in downtown to protect against crime, and Tina Podlodowski keeps lying about Ann Davison. Merck seeks FDA authorization of antiviral COVID-19 pill. Do proper research.
On this episode of Vitality Radio, Jared sits down with Ben Fuehrer of UTZY Naturals to explore one of today's most unavoidable toxic exposures—microplastics. Jared and Ben discuss how microplastics accumulate in the body, what research reveals about their effects on the brain, heart, lungs, and hormones, and why complete avoidance is impossible. You'll learn practical lifestyle steps to reduce exposure and how to support the body's detox systems—especially the liver—to eliminate these pollutants from the body. Ben introduces a groundbreaking daily microplastic-support formula from UTZY that features ingredients like black kale extract, hobamine, green tea extract, milk thistle, and shilajit—a unique combination designed to help the body maintain its natural detoxification and antioxidant balance. This episode offers a clear, realistic view of the modern toxic burden, how to live cleaner without fear, and how to support your body's own resilience—day after day.Products:UTZY Microplastic Daily DetoxUTZY GlyNAC+ Glutathione SupportLiverVitalityEndoCleanseVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals and former malaria drug developer at Walter Reed, joins the Tick Boot Camp Podcast to unpack the science and strategy behind treating babesiosis. Drawing parallels to malaria, Dow explains why tafenoquine (brand: Arakoda), FDA-approved for malaria prevention, is being studied for Babesia, how coinfections (Borrelia, Bartonella) complicate care, and why chronic illness needs a different clinical approach. He previews an upcoming Mount Sinai trial for chronic babesiosis focused on fatigue outcomes and discusses real-world diagnostics using FDA-approved blood donor screening plus PCRs from Galaxy Diagnostics and Mayo Clinic. The conversation also touches on prophylaxis concepts, immune dysregulation, and building a clearer path from anecdote to evidence for the tick-borne disease community. Guest Geoff Dow, BSc, MBA, PhD CEO & Board Member, 60 Degrees Pharmaceuticals Background: Biotechnology (Perth, Australia), PhD in malaria drug discovery, decade at Walter Reed Army Institute of Research, MBA in the U.S. Leads clinical programs exploring tafenoquine for babesiosis. Key Topics & Takeaways Malaria ↔ Babesiosis Parallels: Both are red-blood-cell parasites; acute symptoms driven by red cell destruction. Similar drug targets justify testing some anti-malarials against Babesia. Why Tafenoquine (Arakoda): An 8-aminoquinoline that induces oxidative stress in RBCs; distinct mechanism from atovaquone + azithromycin combo (current standard for acute babesiosis), potentially useful for resistance management. Chronic vs. Acute Disease: Acute babesiosis in immunocompetent patients often responds to standard care; chronic illness remains under-defined and underserved. Coinfections Are Common: Many chronically ill patients present with Borrelia, Bartonella, and Babesia together; diagnostics and treatment need to acknowledge polymicrobial reality. Upcoming Clinical Trial (Mount Sinai): Population: Chronic babesiosis with disabling fatigue, plus Babesia symptoms (e.g., air hunger, anemia) and lab evidence in the last 12 months. Regimen: 4-day loading dose then 200 mg weekly of tafenoquine for 3 months. Outcomes: Patient-reported fatigue (quality-of-life) + monthly molecular testing (FDA blood donor test, Galaxy Diagnostics PCR, Mayo Clinic PCR) during treatment and 3 months post-therapy. Goals: Demonstrate symptom improvement, assess eradication signals, and validate accessible diagnostics against an FDA-accepted assay. Prophylaxis & Post-Exposure Ideas: Animal data suggest short-course tafenoquine can eradicate early Babesia; human prophylaxis trials face feasibility and regulatory hurdles. Diagnostics Gap: Need for standardized, sensitive tools to define chronic babesiosis and track response. This trial also serves as a real-world diagnostic comparison. Immune Dysregulation & IACI: Overlap among long COVID, ME/CFS, post-treatment Lyme—shared theme of immune dysregulation with possible persistent antigen stimulation. Safety Notes: G6PD deficiency is relevant to 8-aminoquinolines; established safety database exists for malaria prevention dosing—critical as studies expand to babesiosis. Notable Quotes “You've got to put some lines in the sand—run the trial, collect data, and move the field forward.” “The best we can do for chronic disease starts with defining it—and validating the diagnostics we use to track it.” “8-aminoquinolines offer a different mechanism than current babesiosis standards—key for resistance and combinations.” Resources Mentioned Arakoda (tafenoquine): FDA-approved for malaria prevention; under study for babesiosis. Diagnostics: FDA-approved Babesia blood donor screen; Galaxy Diagnostics PCR; Mayo Clinic PCR. Organizations & Events: ILADS, Global Lyme Alliance, tick-borne disease conferences. Research Partners: Mount Sinai (NYC), Tulane University (Bartonella/Borrelia collaboration). Who Should Listen Patients with chronic Lyme or chronic babesiosis symptoms (fatigue, air hunger, anemia) Clinicians seeking updates on Babesia treatment research and diagnostics Caregivers and advocates tracking IACI and immune dysregulation science Researchers exploring antimalarial repurposing for tick-borne diseases Call to Action Subscribe to Tick Boot Camp and share this episode with someone navigating chronic tick-borne illness.
This week on ARC News, Nate Williams unpacks three major cultural stories shaping faith and ethics today:– The Supreme Court case out of Colorado dealing with so-called “conversion therapy” laws and what it means for counseling– Louisiana's lawsuit against the FDA over the approval and distribution of abortion pills– The civil war within the LGBTQ community: The "LGB" vs. the "TQ"From an apologetics perspective, Nate explores how believers can respond with truth, grace, and conviction.
John and Jonathan unpack the FDA's surprise approval of a generic abortion pill, the political and legal fallout, and why pro-lifers are demanding a real fight over Mifepristone.
Israelis celebrate reports of a ceasefire; on Culture Friday, John Stonestreet covers the FDA approval of generic mifepristone and Bari Weiss at CBS; and Collin Garbarino reviews Tron: Ares. Plus, the Friday morning newsSupport The World and Everything in It today at wng.org/donateAdditional support comes from Cedarville University—a Christ-centered, academically rigorous university located in southwest Ohio, equipping students for Gospel impact across every career and calling. Cedarville integrates a biblical worldview into every course in the more than 175 undergraduate and graduate programs students choose from. New online undergraduate degrees through Cedarville Online offer flexible and affordable education grounded in a strong Christian community that fosters both faith and learning. Learn more at cedarville.edu, and explore online programs at cedarville.edu/onlineFrom Covenant College, where Christian faculty equip students for their callings through hard ideas, deep questions, and meaningful work. covenant.edu/worldAnd from Ambassadors Impact Network, helping entrepreneurs who are looking for more than just funding. Discover a community of Christian faith-led investors. More at ambassadorsimpact.com
This week, Ali sits down with Dr. Mark Ratner, Chief Science Officer at Theralogix and one of the country's leading experts in reproductive health and nutritional science.After 30 years in private practice focused on male fertility, Dr. Ratner has seen firsthand how confusing — and sometimes misleading — the supplement world can be. In this eye-opening conversation, he and Ali unpack what's actually backed by science when it comes to fertility supplements, how to choose products that are truly evidence-based, and the importance of transparency in a market full of mystery formulas and marketing claims.They also dive into OvaNAD+, a Theralogix supplement specifically designed to support egg health and mitochondrial function. Mark and the Theralogix team are also offering a special discount to Infertile AF listeners. Save 15% at Theralogix.com with code INFERTILEAF. For more, go to: theralogix.comEPISODE SPONSORS: BEAUTIFUL BIRD AND WORK OF ARTAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe latest book in the Work of ART series, “Beautiful Bird” tells the story of three parents, one incredible boy and a family built with love—and a little bit of science.Pre-orders are available now! The first 150 copies will be Personalized, Signed and Numbered! Don't miss out on this limited edition! Tap the link in bio and stories to order your copy today.When Helen decides to have a baby on her own, she welcomes Jack Bird into the world through IUI with the help of her friend, Aaron. But when Jack is born and needs extra care in the NICU, Aaron and his partner, Blake, fall in love with Jack, too. Together, the three join forces to raise Jack, proving that family isn't about how you start—it's about how you grow.Order yours now at https://www.infertileafgroup.com/booksFERTILITY RALLYIG: @fertilityrallywww.fertilityrally.comNo one should go through infertility alone. Join the Worst Club with the Best Members at fertilityrally.com. We offer 5 to 6 support groups per week, three private Facebook groups, tons of curated IRL and virtual events, and an entire community of more than 500 women available to support you, no matter where you are in your journey.Join today at link in bio on IG @fertilityrally or at www.fertilityrally.com/membershipPHERDALIG: pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
In this week's episode, we wade into the bloody (and sometimes gory) side of science. Part 1: Shawn Musgrave wants to donate blood, but runs headfirst into the FDA's lifetime ban on gay men as donors. Part 2: While working with the condor recovery program, Molly Astell opens a freezer to find every researcher's nightmare. Shawn Musgrave is a lawyer, journalist, lawyer-who-represents-journalists, and somewhat recent transplant to New York. His work has appeared in The Intercept, POLITICO, The Verge, VICE, and the Boston Globe, among other publications, as well as in the Netflix docuseries How to Fix a Drug Scandal. Molly Astell is a wildlife biologist who originally never wanted to be one of those "bird people", yet went on to exclusively work with endangered birds in their career. Fourteen of those years were spent working as part of the California condor recovery program in a variety of different roles, mostly with the wild condors in southern California, but also with the captive breeding birds in Boise, ID. Currently, they are a graduate student at Boise State University doing research with condor data they helped to collect, and is discovering the joys of teaching biology to undergraduates.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
What if the key to healing pain, boosting brain health, and even reducing inflammation was as simple as light? In this groundbreaking episode, nine-time Emmy winner David Sams sits down with inventor Tom Kerber to explore the science and miracles behind SunPowerLED's red light therapy. From relieving arthritis, back pain, and migraines to supporting recovery from traumatic brain injuries, Parkinson's, autism, and even vision challenges, this conversation uncovers how powerful light technology is transforming health and wellness. You'll hear incredible real-life stories—people regaining mobility after decades of pain, improved sleep, reduced anxiety, and even renewed cognitive function. Tom explains why his FDA-registered devices go far beyond the typical red-light panels you see in spas, offering medical-grade near infrared light therapy that penetrates deeply to help the body heal from the inside out. If you've ever searched for answers about how red-light therapy works, best red-light therapy devices, red-light therapy for pain relief, inflammation, arthritis, brain health, or anti-aging benefits, this episode is packed with hope, science, and practical insights. ✨ Learn how light may be the future of natural healing.✨ Discover the difference between low-power light panels and high-powered therapeutic devices.✨ Hear why Tom believes this technology is nothing short of modern-day miracles. Listen now and see why people everywhere are calling red light therapy a life-changing breakthrough.
AlabamaSen.Britt calls on Dems to Work and hold conversation at the same timeSen. Tuberville says Sharia Law has no place in the US at any levelTwo AL congressman criticize the FDA's generic abortion drug approvalFather of injured student in Tuscumbia not stopping his pursuit for answersA federal judge rules against the ATFE and in favor of firearm dealersHaley Harris is in AL jail after extradition to face kidnapping chargesDNA testing for local fish only to happen at Gulf Shores Shrimp FestivalNational200 US troops head to the Middle East to help in peace deal and transitionVA grand jury issues indictment of mortgage fraud for NY AG Letitia JamesFederal judge issues injunction against National Guard in city of ChicagoDominion Voting Systems has been acquired by a Republican!Harper Collins apologizes for book claiming Jeffery Epstein introduced Melania to Donald Trump
The integrity of evidence-based policy is under threat when political agendas override scientific rigor. In this episode, Dr. Robert Califf, former FDA Commissioner and cardiologist, reflects on his experience leading the FDA and the agency's critical role in protecting public health through rigorous, science-based regulation across multiple sectors. He warns that political interference, disinformation, and mistrust threaten health outcomes but believes meaningful collaboration can still restore integrity and progress. Tune in and learn how protecting science-based regulation may be one of the most important public health actions of our time! Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with Dr. Mark Schoenberg—renowned urologist and Chief Medical Officer at UroGen® Pharma—for a wide-ranging conversation about the evolution of bladder cancer research, treatment, and patient advocacy. Dr. Schoenberg shares the story behind BCAN's founding, the early challenges of raising awareness, and the innovations that are reshaping care today, including the development of non-surgical therapies like ZUSDURI™ (mitomycin) for intravesical solution, a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove the tumor and it did not work or is no longer working. From his decades of patient-centered work to his role in pioneering new approaches with UroGen, Dr. Schoenberg offers insights into where the field has been and the promising future ahead. Tune in to hear a fascinating mix of history, science, and hope for patients and families impacted by bladder cancer. Please see the link to the full Prescribing Information on the podcast web page or available at www.zusduri.com. ZUSDURI Prescribing Information ZUSDURI Patient Information Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove tumor and it did not work or is no longer working. ZUSDURI™ Important Safety Information You should not receive ZUSDURI™ if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI™. Before receiving ZUSDURI™, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI™ can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI™. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI™. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 6 months after the last dose. Males being treated with ZUSDURI™: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI™ passes into your breast milk. Do not breastfeed during treatment with ZUSDURI™ and for 1 week after the last dose. How will I receive ZUSDURI™? You will receive your ZUSDURI™ dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI™ according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI™, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI™: ZUSDURI™ may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI™ include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information. JELMYTO® Important Safety Information You should not receive JELMYTO® if you have a hole or tear (perforation) of your bladder or upper urinary tract. Before receiving JELMYTO®, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant. JELMYTO® can harm your unborn baby. You should not become pregnant during treatment with JELMYTO®. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO®. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO® and for 6 months after the last dose. Males being treated with JELMYTO®: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO® and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if JELMYTO® passes into your breast milk. Do not breastfeed during treatment with JELMYTO® and for 1 week after the last dose. Tell your healthcare provider if you take water pills (diuretic). How will I receive JELMYTO®? Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO® treatment. You will receive your JELMYTO® dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO® according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses. JELMYTO® is given to your kidney through a tube called a catheter. During treatment with JELMYTO®, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving JELMYTO®: JELMYTO® may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. JELMYTO® may cause serious side effects, including: Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO®. Bone marrow problems. JELMYTO® can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO®. Your healthcare provider may need to temporarily or permanently stop JELMYTO® if you develop bone marrow problems during treatment with JELMYTO®. The most common side effects of JELMYTO® include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please click here for JELMYTO® Full Prescribing Information, including the Patient Information, for additional information.
With a new president of U.S. pharma at the helm—and two key FDA approvals now in the books—Boehringer Ingelheim is sharpening its focus on the lucrative American market. In this week’s episode of “The Top Line,” we dive into Boehringer Ingelheim’s latest regulatory successes, two crucial launches, and the German company’s expanding commercialization push in the U.S. Fierce Pharma’s Fraiser Kansteiner sits down with Brian Hilberdink—who joined Boehringer as president of U.S. human pharma in February—to discuss his game plan to further unlock the American market and capitalize on key BI green lights in idiopathic pulmonary fibrosis and lung cancer. To learn more about the topics in this episode: Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med Hernexeos Boehringer Ingelheim breathes new life into lung fibrosis field with FDA approval for Jascayd 'Crossing fingers': Boehringer awaits key FDA decisions to spearhead 'maturing' pipeline Chutes & Ladders—Boehringer snatches up LEO exec for US pharma team See omnystudio.com/listener for privacy information.
Cereno Scientific CEO Sten Sörensen discusses how his company is repurposing a 60-year-old epilepsy drug as a potential game-changer for pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Learn about their promising Phase IIa results that showed improved heart function and reduced mortality risk, the FDA fast track designation they recently received, and their strategy for advancing two rare disease programs toward pivotal trials. A fascinating look at drug repurposing, epigenetic modulation, and the challenges of developing therapies for high unmet need patient populations.
Update on the alleged arsonist Jonathan Rinderknecht who's accused of starting the Pacific Palisades fire in early January 2025. An LA hotspot, Great White on Melrose, is accused of segregating its customers by race, according to a TikTok clip posted by a customer who is Asian. An Inland Empire woman is facing murder charges after she injected her patient's buttocks with silicone as part of a Brazilian butt lift procedure, which isn't FDA approved. The woman had no medical license. The Katie Porter bad interview on CBS is blowing up. She's running for governor in California and was asked about 40% of California voters who voted for Donald Trump.
CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; and the FDA grants Breakthrough therapy designation to a novel influenza therapy.
Megyn Kelly is joined by Buck Sexton, co-host of "The Clay and Buck Show," to talk about Trump's massive Middle East deal between Israel and Hamas, Trump's legacy and skills as a dealmaker, how even the left and media are being forced to give him credit now, what happens next in the Middle East, the truth about Hamas and the false equivalency some make with Israel, and more. Then Dr. Patrick Soon-Shiong, CEO of Los Angeles Times Media Group, joins to talk about why he stopped his paper from publishing their Kamala Harris endorsement, his reaction to the fallout, his decision to take the LA Times public and give power to the audience, Bari Weiss taking over as head of CBS News, the future of the media, his work in trying to find a cure for cancer, his challenge trying to get the FDA to approve this new procedure, the effectiveness of his method, why he thinks President Trump could be the person to implement this massive scientific breakthrough, and more. Soon-Shiong- https://x.com/drpatsoonshiongSexton- https://www.youtube.com/@BuckSexton Unplugged: Switching is simple, Visit https://Unplugged.comand order your UP phone today!Masa Chips: Get 25% off your first order | Use code MK at https://MASAChips.com/MKVandy Crisps: Get 25% off your first order | Use code MK at https://vandycrisps.com/MKGeviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Follow The Megyn Kelly Show on all social platforms:YouTube: https://www.youtube.com/MegynKellyTwitter: http://Twitter.com/MegynKellyShowInstagram: http://Instagram.com/MegynKellyShowFacebook: http://Facebook.com/MegynKellyShow Find out more information at:https://www.devilmaycaremedia.com/megynkellyshow Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Patrick Bet-David sits down with investigative journalist Gerald Posner to expose how the government protected Big Pharma during the OxyContin crisis, the FDA's cover-ups, and the Vatican's hidden financial dealings.———Ⓜ️ CONNECT ON MINNECT WITH GERALD POSNER: http://bit.ly/3WsdS8PⓂ️ PBD PODCAST CIRCLES: https://bit.ly/4mAWQAP
The government shutdown continues with no obvious end in sight, and while it theoretically should not affect entitlement programs like Medicare and Medicaid, the lapse of some related authorizations — like for Medicare telehealth programs — is leaving some doctors and patients high and dry. Meanwhile, the FDA quietly approved a new generic abortion pill, prompting a not-so-quiet reaction from anti-abortion groups. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sarah Karlin-Smith of Pink Sheet join KFF Health News' Julie Rovner to discuss those stories and more. Also this week, Rovner interviews Sarah Grusin of the National Health Law Program about the GOP's misleading claims that Democrats shut down the government in pursuit of free health care for immigrants who are in the country illegally. Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too: Julie Rovner: The Washington Post's “How Some Veterans Exploit $193 Billion VA Program, Due to Lax Controls,” by Craig Whitlock, Lisa Rein, and Caitlin Gilbert. Tami Luhby: The Washington Post's “Trump Plan Would Limit Disability Benefits for Older Americans,” by Meryl Kornfield and Lisa Rein. Sarah Karlin-Smith: The New York Times' “It's Just a Virus, the E.R. Told Him. Days Later, He Was Dead,” by Lisa Miller. Alice Miranda Ollstein: The 19th's “Ice Fears Put Pregnant Immigrants and Their Babies at Risk” by Mel Leonor Barclay and Shefali Luthra. Hosted on Acast. See acast.com/privacy for more information.
Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinectedin enters the chat with a recent FDA approval. Next up - tarlatamab? IMforte (maintenance lurbinectedin + atezolizumab): https://doi.org/10.1016/S0140-6736(25)01011-6 DeLLphi-303 (phase 1b maintenance tarlatamab + ICI): https://doi.org/10.1016/S1470-2045(25)00480-2
It's Thursday, October 9th, A.D. 2025. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com. I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Pakistani pastor dies after 13-year jail sentence A pastor in Pakistan died on Sunday after languishing in prison for 13 years. Pastor Zafar Bhatti founded Jesus World Mission Church ministry. Back in 2012, he was falsely accused of insulting Islam. Authorities finally overturned his conviction this month, releasing him last Wednesday. The 62-year-old pastor died days after from cardiac arrest at his home. The British Asian Christian Association helped defend the pastor in court. The organization stated, “Though his earthly journey has ended, Zafar's faith, endurance, and ultimate vindication remain a powerful testament to hope in Christ amidst persecution.” Nigerian Anglican Church appalled that woman chosen to be new church head The Anglican Church of Nigeria declared spiritual independence from the Church of England on Tuesday. The announcement came in response to the Church of England's appointment of Sarah Mullally as the Archbishop of Canterbury. She is the first woman to hold the position. She also supports abortion and faux homosexual marriage. Archbishop Henry Ndukuba is the Primate of the Church of Nigeria. He stated, “[Mullally's] appointment marks a tragic departure from biblical orthodoxy. . . . We remain Anglicans — but not under Canterbury. Our loyalty is to Christ and the truth of His Word, not to institutions that have abandoned it.” Police arrest man intent on blowing up church with Supreme Court Justices In the United States, police arrested a man on Sunday who had hundreds of explosive devises outside of St. Matthews Cathedral in Washington, D.C. Police made the arrest before an annual service traditionally attended by U.S. Supreme Court justices. According to court records, the man's notebook expressed animosity toward Supreme Court justices, the Catholic Church, Jews, and immigration enforcement officials. FBI cuts ties with God-hating Southern Poverty Law Center The Federal Bureau of Investigation announced last week it has cut ties with the Southern Poverty Law Center. The far-left nonprofit is known for listing conservative and Christian organizations as “hate groups,” primarily because they affirm God's design for sexuality and marriage. FBI Director Kash Patel posted on X, “The Southern Poverty Law Center long ago abandoned civil rights work and turned into a partisan smear machine. Their so-called ‘hate map' has been used to defame mainstream Americans and even inspired violence. That disgraceful record makes them unfit for any FBI partnership.” Florida, Louisiana, Missouri & Texas sue FDA over mail-order Abortion Kill Pill The state of Louisiana joined a lawsuit against the Food and Drug Administration on Monday. Florida, Missouri, and Texas are also on the case. They are challenging the FDA's 2023 policy that allows mail-order abortion drugs. Louisiana's filing states, “Every year, doctors and activists in states like California and New York mail a U.S. Food and Drug Administration (FDA)-approved abortion drug called mifepristone to thousands of Louisiana residents for the express purpose of causing abortions in Louisiana that are blatantly unlawful.” Gold hit $4,000 per ounce first time ever On Tuesday, spot gold prices hit $4,000 per ounce for the first time in history. That's up 50% from January. Silver is up 60% this year. The demand for gold is up as investors hedge against economic uncertainty. Financial analyst Rhona O'Connell told Reuters, “Background factors are much the same as before, in terms of geopolitical uncertainty, with the added spice of the (U.S.) government shutdown.” Prison Fellowship and Bible League to send 620,000 Bibles to prisoners And finally, Prison Fellowship International and Bible League International are partnering to distribute over half a million Bibles. The 620,000 Bibles will go to prisoners in 20 countries over the next five years. Frank Lofaro with Prison Fellowship International said, “God's Word has the power to reach prisoners in their darkest moments with the light of Jesus Christ. Through this partnership, prisoners who come to know Jesus through our evidence-based, in-prison programs are equipped to grow in their faith through a Bible that they can understand and that speaks to their circumstances.” Luke 4:18 says, “The Spirit of the LORD is upon Me, because He has anointed Me to preach the gospel to the poor; He has sent Me to heal the brokenhearted, to proclaim liberty to the captives and recovery of sight to the blind, to set at liberty those who are oppressed.” Close And that's The Worldview on this Thursday, October 9th, in the year of our Lord 2025. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.
This podcast is sponsored by YARAL Pharma. In this episode, we are focusing on the management of hypothyroidism -- a treatable, but not curable condition – and will explore unique challenges for patients with hypothyroidism in long-term care – from tolerability and formulation considerations to consistent dosing and patient needs. Dr. Tamara Ruggles is not affiliated with YARAL Pharma. All views and opinions regarding hypothyroidism are solely her own and are not attributable to YARAL or the Pharmacy Podcast Network. IMPORTANT SAFETY INFORMATION for levothyroxine sodium capsules INDICATION AND USAGE Levothyroxine sodium capsules are L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer Limitations of Use: Levothyroxine sodium capsules are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine sodium capsules may induce hyperthyroidism. Levothyroxine sodium capsules are not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis WARNING: NOT FOR THE TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium capsules, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. Contraindications Uncorrected adrenal insufficiency Warnings and Precautions Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate Levothyroxine sodium capsules at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium capsules treatment Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone reabsorption and decrease bone mineral density. Give the lowest effective dose Adverse Reactions Common adverse reactions with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central Nervous System: headache, hyperactivity, nervousness, anxiety, irritability, emotional ability, insomnia Musculoskeletal: tremors, muscle weakness Cardiovascular: palpitations, tachycardia, arrythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal (GI): diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Adverse Reactions in Children Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height. Seizures have been reported rarely with the institution of levothyroxine therapy. Hypersensitivity Reactions Hypersensitivity reactions to inactive ingredients (in this product or other levothyroxine products) have occurred in patients treated with thyroid hormone products. These include urticaria, pruritis, skin rash, flushing, angioedema, various GI symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur. Drug Interactions: Many drugs and some foods can exert effects on thyroid hormone pharmacokinetics (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine sodium capsules. Administer at least 4 hours before or after drugs that are known to interfere with absorption. See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism. To report SUSPECTED ADVERSE REACTIONS, contact Yaral Pharma Inc. at 1-866-218-9009, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Full Prescribing Information, including Boxed Warning, go to www.yaralpharma.com/levothyroxine-pi.
“We don't view a person with chronic pain as someone who has a chronic illness and the effect of that is we can't follow patients continuously over prolonged periods of time,” says Dr. Jacob Hascalovici, a neurologist and pain specialist based in New York City. In co-founding Bliss Health, Dr. Jacob, as he is known, has set out to create a continuous care model for chronic pain treatment that matches the approach taken for patients with diabetes or high blood pressure. The Bliss Health formula includes an initial meeting with a physician that produces a care plan; remote therapeutic monitoring on an ongoing basis; and a monthly meeting with a nurse to review data and determine next steps, including additional appointments with physicians as needed. All of this occurs via a digital platform which provides a welcome option for patients with mobility issues and can fill gaps in access to specialists, especially in rural areas. Dr. Jacob is also hoping to make chronic pain patents feel respected, which is not always the case in their encounters with the healthcare system. “Because pain is not something that can be seen or measured, oftentimes patients feel marginalized, dismissed and disempowered by providers.” Join Raise the Line host Lindsey Smith for a valuable conversation that also touches on policy changes that could strengthen telemedicine, and has details on the first non-opioid based pain medication to receive FDA approval in over 20 years.Mentioned in this episode:Bliss Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Bishop Michael Burbidge joins this week to discuss not only his important work making sure all of the Arlington Diocese's Catholic schools are inclusive to children with special needs, but also to share his experience praying the Rosary with them marking the feast day of Our Lady of the Rosary. His Excellency also voices his concern over the threat of a constitutional amendment being considered on abortion within Virginia and why the consistent life ethic must always be applied to our understanding of life at any stage. Jennie Bradley Lichter also joins as she is gearing up for her first march as president of the March for Life, revealing the theme, why the recent FDA abortion news is so troubling, and a very important case that all pro-lifers should know about. Msgr. Roger Landry also talks about Cardinal John Henry Newman, soon-to-be-doctor of the Church as we celebrate his feast day today. Catch the show every Saturday at 7amET/5pmET on EWTN radio!
How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10).Show Notes:Finding Winners In Biotech, Probably The Riskiest SectorSyndax Pharmaceuticals: A Tale Of Two Drug LaunchesArcutis Biotherapeutics: Another Approval Under Their BeltEpisode transcriptsFor full access to analyst ratings, stock and ETF quant scores, and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
We love to hear from our listeners. Send us a message.Welcome to Episode 113 of Cell & Gene: The Podcast. Host Erin Harris is joined by Thorsten Gorba, Ph.D., VP Process Development at Aspen Neuroscience to explore how the company is advancing the field of cell therapy manufacturing. Aspen Neuroscience stands at the forefront of integrating machine vision and AI/ML to assess induced pluripotent stem cell (iPSC) colony quality by offering a transformative approach to move beyond the subjective nature of manual evaluation. Dr. Gorba discusses how these technologies bolster reproducibility and scalability and help reduce variability in starting materials. He also covers the regulatory angle, including how the FDA is evaluating digital quality control tools. Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
Today on the Pro-Life Podcast, we're celebrating the closure of Planned Parenthood's largest clinic! But... the FDA just approved a generic pill that could make abortions cheaper and easier. Who's to blame? We talk about all this and more on our 100th episode! Links: Houston's Mega-Planned Parenthood Closed TODAY https://texasrighttolife.com/houstons-mega-planned-parenthood-closed-today/FDA Approves New Generic Abortion Drug to Kill More Babies https://www.lifenews.com/2025/10/02/fda-approves-new-generic-abortion-drug-to-kill-more-babies/Ask President Trump to stop abortion pills: https://texasrighttolife.com/contact-your-elected-officials/Follow us: @TexasRightToLifeDonate: TexasRightToLife.com/Donate–Join Patriot Mobile: https://patriotmobile.com/texasrighttolife/ Get a FREE MONTH when you use the offer code TRTL.Find your favorite Pro-Life gear at Store.TexasRightToLife.com and use code PODCAST at checkout for 15% off. You can subscribe to the ProLife Podcast at:Apple Podcasts: https://podcasts.apple.com/us/podcast/prolife-podcast/id1612172721Spotify: https://open.spotify.com/show/3povSwEEJ37aESIoeqPx2qCastbox: https://castbox.fm/channel/id4813902?country=usRadioPublic: https://radiopublic.com/prolife-podcast-6rmx3NAmazon Music: https://music.amazon.com/podcasts/1dea935a-608a-4fed-8174-427f256e9d72/prolife-podcastiHeart Radio: https://www.iheart.com/podcast/269-prolife-podcast-105028810/And Pocket Casts: https://pca.st/9gmni47j FOLLOW US:Facebook - https://www.facebook.com/TexasRightToLife/Instagram - https://www.instagram.com/txrighttolife/X - https://x.com/txrighttolifeWebsite - https://texasrighttolife.com
In today's episode, we had the pleasure of speaking with Joseph Jacob, MD, MCR, about the FDA approval of the gemcitabine intravesical system (formerly TAR-200; Inlexzo) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer. Dr Jacob is an associate professor of urology and the director of Urologic Oncology in the Department of Urology at State University of New York Upstate Medical University in Syracuse. In our exclusive interview, Dr Jacob discussed the significance of this approval, key efficacy findings from the pivotal phase 2b SunRISe-1 trial (NCT04640623), and the TAR-200 administration procedure, which he describes as straightforward for practitioners and convenient for patients.
Hunter syndrome is caused by the body's inability to produce a critical enzyme needed to break down cellular waste. The condition can cause damage to organs throughout the body as well as to the brain. A new generation of therapies in development, including a gene therapy currently under review by the U.S. Food and Drug Administration, that has the potential to address the neurological symptoms of the disease. Still, patient advocates have been frustrated by regulatory delays and are seeking to push the FDA and Congress to take action. We spoke with Kristin McKay, CEO of the Hunter syndrome patient advocacy organization Project Alive, about the need for new therapies, the importance of early detection, and the patient community's concerns with regulatory delays in approving needed treatments. An editor's note: Since recording this podcast, the FDA granted accelerated approval to Stealth Biotherapeutics' Forzinity for Barth syndrome, which is referenced in the discussion.
Howie and Harlan discuss the roots of the crisis in emergency departments, the lack of oversight for hydration spas, new approaches in blood pressure treatment, an ingenious method to prevent malaria, and the CDC's backward steps on vaccines. Links: Emergency Departments “I'm an ER doctor. JD Vance's claims about immigrants and wait times are just wrong.” “It's Just a Virus, the E.R. Told Him. Days Later, He Was Dead.” Video of Ron Paul: “Should society let uninsured die?” American College of Emergency Physicians: Understanding EMTALA “Explaining the G.O.P.'s Misleading Talking Point on the Looming Shutdown” Centers for Medicare and Medicaid: Emergency Medical Treatment & Labor Act (EMTALA) Health & Veritas Ep. 188: Kate Heilpern: Jumping into the Deep End Health & Veritas Ep. 47: Dr. Jeremy Faust: Is COVID Over? It's Complicated. Jeremy Faust: “Inside Medicine Read-Through: Commentary on the New York Times article about a tragic ER case” Harlan Krumholz: “Early Warning Scores With and Without Artificial Intelligence” Howard Forman: “Why Hospitals Need to Stop Boarding Patients in Emergency Rooms” Howard Forman: “How to Keep Emergency Rooms Focused on True Emergencies” The Revolving Door “Peter Marks, FDA vaccine regulator ousted by RFK Jr., joins Eli Lilly” Peter Marks Resignation Letter “Peter Marks, FDA's top vaccine regulator, forced out” “Fired C.D.C. Director Describes Clashes With Kennedy and Turmoil at Agency” “Ex-CDER chief Patrizia Cavazzoni becomes Pfizer's chief medical officer” Hydration Spas Howard Forman: “State Policies and Facility Practices of IV Hydration Spas in the US” Health & Veritas Ep. 123: Margo Harrison: Women's Health as a Path to Empowerment “Hydration spas are largely unregulated, study finds” New Developments in Blood Pressure Treatment “Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension” “AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win, bolstering differentiation case” Harlan Krumholz: “The Disquieting Plateau” “Under new guidelines, more Americans meet the criteria for high blood pressure” “2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines” “Permethrin-Treated Baby Wraps for the Prevention of Malaria” AI in Medicine: Doximity, OpenEvidence, and UpToDate “OpenEvidence raises $210M, unveils AI agents built for advanced medical research” Health & Veritas, Ep. 183: Seth Berkowitz: The Power Problem “Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers” “A long-trusted physician's reference finally catches the AI wave” Congenital syphilis Health & Veritas Ep. 178: Sarah DeSilvey: Creating Space for Healing “Are STIs truly declining, or is our data just not very good? What the 2024 CDC STI report really shows” “Why Syphilis Cases in Newborns Are Rising Even as STIs Decline” MMR Vaccine “Acting CDC director calls to 'break up' the measles, mumps and rubella vaccine into three shots” “Worried about splitting up the MMR vaccine into three separate shots? You should be, this doctor says” “More measles cases confirmed in South Carolina, Michigan as US total climbs to 1,563” Nobel Prizes and Science at Yale “Nobel Prize in Physiology or Medicine Is Awarded for Work on Immune Systems” “Nobel Prize in Physiology or Medicine 2025” “Yale's Michel H. Devoret wins 2025 Nobel Prize in Physics” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.
Top headlines for Thursday, October 9, 2025Maverick City Music's Chandler Moore has filed a federal lawsuit, alleging the worship collective's CEO diverted millions of dollars. Louisiana takes the FDA to court over the mailing of abortion pills into the state. And across the Atlantic, a new survey warns that thousands of churches in the U.K. could close within five years. 00:11 Christopher Yuan's recovery from fall 'exceeding expectations'00:55 Pastor used more than $400K of church funds for personal items01:53 Chandler Moore sues Maverick City Music CEO02:41 Louisiana sues Trump's FDA over abortion pill mailing rules03:29 Man arrested at DC church had 200 homemade explosives, manifesto04:17 Thousands more churches to close in UK over next 5 years: study05:06 Red carpet premiere of 'Soul on Fire' spotlights real-life heroesSubscribe to this PodcastApple PodcastsSpotifyGoogle PodcastsOvercastFollow Us on Social Media@ChristianPost on TwitterChristian Post on Facebook@ChristianPostIntl on InstagramSubscribe on YouTubeGet the Edifi AppDownload for iPhoneDownload for AndroidSubscribe to Our NewsletterSubscribe to the Freedom Post, delivered every Monday and ThursdayClick here to get the top headlines delivered to your inbox every morning!Links to the NewsChristopher Yuan's recovery from fall 'exceeding expectations' | U.S.Pastor used more than $400K of church funds for personal items | U.S.Chandler Moore sues Maverick City Music CEO | EntertainmentLouisiana sues Trump's FDA over abortion pill mailing rules | PoliticsMan arrested at DC church had 200 homemade explosives, manifesto | U.S.Thousands more churches to close in UK over next 5 years: study | Church & MinistriesRed carpet premiere of 'Soul on Fire' spotlights real-life heroes | Entertainment
For Episode 86, Joel and Andrene observe 1994's “Junior”. After the FDA denies his request to test a new fertility drug on women, male scientist Dr. Hesse (Arnold Schwarzenegger) uses the medicine on himself and becomes pregnant in order to advance his research.
In this episode of Disruption/Interruption, host KJ sits down with Jim Foote, CEO and founder of First Ascent Biomedical. Jim shares his personal journey from technology executive to cancer care innovator, after his son’s diagnosis changed his life. Discover how he’s disrupting the status quo in oncology with AI-driven, personalized medicine that’s giving new hope to patients and families. Key Takeaways: The Problem with Standard Cancer Care [3:53]The standard of care treats patients as if they are the same, but everyone is unique. This approach works two-thirds of the time, but leaves one-third of patients with few options. Functional Precision Medicine [13:04]Jim’s company tests up to 152 FDA-approved drugs on a patient’s biopsy to find the most effective treatment, providing doctors with data-driven options tailored to each individual. AI and Technology are Transforming Oncology [28:05]Advances in AI, robotics, and cloud computing have converged, making personalized cancer treatment faster, more affordable, and more effective than ever before. Impact and Future Vision [26:51]Jim’s goal is for every cancer patient to receive individualized treatment from the moment of diagnosis, improving outcomes and reducing unnecessary side effects. Quote of the Show (14:40):“I literally have gone from trying and hoping to testing and choosing.” — Jim Foote Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jim Foote: LinkedIn: http://www.linkedin.com/in/jim-foote Company Website: https://firstascentbiomedical.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.
On this episode of Vitality Radio, Jared dives deep into one of the most overlooked yet essential nutrients: vitamin B1, also known as thiamine. While other B vitamins often take the spotlight, B1 is critical for energy production, nerve function, and overall resilience. Jared explains why not all forms of B1 are created equal, highlighting the difference between standard water-soluble versions and the more bioavailable fat-soluble forms such as benfotiamine and sulbutiamine. You'll learn how benfotiamine supports nerve health and circulation, while sulbutiamine penetrates the brain to deliver steady energy and focus without the jitters or crash of stimulants. Drawing from history, research, and his own formulating experience, Jared shares how these powerful forms of B1 help protect against sugar damage, reduce oxidative stress, and enhance everyday vitality. Whether you struggle with fatigue, nerve challenges, or simply want more consistent energy, understanding the right form of vitamin B1 could be a game-changer.Products:Ultimate Vitality MultiNerve ReverseActive B ComplexBenfotiamine Aloe Life Detox Plus + CellCore Binder (Vitality Radio POW! Product of the Week Buy any CellCore Binder and Get Aloe Life Detox Plus Formula FREE with PROMO CODE: POW12)#543: How to Choose the Right Binder for Detox, Parasites, Mold, and MetalsAdditional Information:#417: The B Vitamins: Understanding Their Roles and What They Can Do For YouVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
Jackie is joined by the incredible Michelle Collins to discuss, fixing and being fixed in relationships, bringing back bullying and shame, and why the housewives need a villain.Thanks for supporting my sponsors:Honeylove: For a limited time, get 20% off your entire order at www.honeylove.com/bibleHome Chef: For a limited time, get 50% off and free shipping for your first box. Plus free dessert for life at www.HomeChef.com/BIBLEPique: With the Deep Hydration Protocol, get 20% off for life when you subscribe. Plus a complimentary gift to elevate your routine at www.PiqueLife.com/BIBLEBetterHelp: Get 10% off your first month at www.BetterHelp.com/BITCHBIBLEAddyi: Check out the FDA-approved treatment for certain premenopausal women who are bothered by low libido and want their sex drive back at www.Addyi.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Kara's in The Secret Room to answer the question: What happens when your mom moves her secret lover into the basement? HERS Visit forhers.com/SECRET for your personalized weight loss treatment options. Hers Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life! HomeChef.com/SECRET. Must be an active subscriber to receive free dessert. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET. PICTURES Kara shared pictures of herself, her mom, her sister and boyfriend! They are waiting for you on Threads, Facebook, Instagram and X. Handle: @secretroompod. YOUTUBE The Secret Room is now on YouTube! THE SECRET ROOM | UNLOCKED Ella is back for the conclusion of her secret: her parents didn't tell her she had a deadly disease. After the devastating passing of her little brother from the same condition, Ella began to experience intense pain herself. She tells us about her bold journey that spanned two continents seeking the answers she couldn't get at home. Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See all our sponsors past and present, and their offers, many of which are still valid: secretroompodcast.com/codes FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page! Just ask to join, all are welcome. :) YOUR SECRET Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!
Brigham Buhler is a healthcare entrepreneur transforming America's broken system. As founder of Ways2Well, owner of Revive Rx Pharmacy, and an investor in psychedelic research, he champions a model of care that prioritizes patients over profits through preventative medicine, transparency, and innovation. His work is guided by a few core convictions: -Former insider's perspective: With deep experience navigating the corrupt systems of pharmacy benefit managers (PBMs), insurance companies, and the FDA, Brigham knows firsthand how the system is stacked against patients. -Uncompromising advocate: He pushes to expose and dismantle the corporate capture of American healthcare. -Bold truth-teller: He believes in revealing the realities of the insurance Ponzi scheme and providing practical ways to bypass outdated systems. -Relentless reformer: He is dedicated to replacing a model that profits off sickness with one centered on health, longevity, and patient empowerment. Today's Sponsors: Black Rifle Coffee: https://www.blackriflecoffee.com LMNT: https://www.drinklmnt.com/clearedhot
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter addresses the recent headlines linking acetaminophen (Tylenol) use during pregnancy to autism in exposed children. Recognizing the confusion these claims have sparked among patients, listeners, and the broader public, Peter uses this episode to provide a framework for thinking critically about complex conditions and the research related to them. He highlights the dramatic rise in autism diagnoses over recent decades, noting that multifactorial conditions rarely have a single cause, and emphasizes the importance of resisting oversimplified explanations. Peter also stresses that humans are not naturally wired for scientific thinking, making disciplined frameworks like the Bradford Hill criteria essential for evaluating causality in epidemiology. Ultimately, he uses this framework to explore the evidence surrounding acetaminophen use during pregnancy and its potential link to autism. We discuss: Laying the groundwork for this discussion, the rise in autism rates, and the value in using frameworks [1:00]; The FDA pregnancy drug categories, where Tylenol falls within that framework, and a structured method for evaluating scientific evidence and causality [6:00]; What exactly are the claims being made about acetaminophen and autism? [13:45]; The increase in autism rates and why so many things are being linked to autism: the multiple comparisons problem [15:00]; Evaluating the review paper that triggered the recent concern over acetaminophen and autism [21:45]; Breaking down the largest studies on prenatal Tylenol exposure and autism: is there a causal link? [35:00]; Why observational studies can't prove causality, the role of confounding variables, and the importance of frameworks like the Bradford Hill criteria [43:30]; Applying the Bradford Hill criteria: testing the case for Tylenol and autism [45:45]; Putting it all together to answer the question: Does acetaminophen use during pregnancy increase the risk of autism? [56:15]; If autism risk is overwhelmingly genetic, what explains the dramatic rise in autism diagnoses? [59:15]; Other risk factors for autism: parental age, maternal health, environment, and where Tylenol fits in [1:09:15]; Medication use during pregnancy: balancing risks, benefits, and FDA categories [1:15:15]; Considerations for taking Tylenol during pregnancy [1:19:30]; Final thoughts: critical thinking, balanced risk assessment, and the importance of context when evaluating medications like Tylenol during pregnancy [1:22:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
© 2020-2025 Ivy Podcast Discovery LLC
